Wall Street weighs in on Gilead as shares fall on possible U.S. HIV cuts

Published 19/03/2025, 19:04
©  Reuters

Investing.com -- Gilead Sciences shares dropped more than 3% Wednesday following a Wall Street Journal report that the Health and Human Services Department is considering major cuts to federal funding for domestic HIV prevention programs. 

Analysts, however, see only a limited impact on the company’s financial outlook.

According to BMO Capital, the potential removal of the Centers for Disease Control and Prevention’s (CDC) $1.3 billion in funding represents more of a “headline risk” rather than a serious threat to Gilead’s pre-exposure prophylaxis (PrEP) franchise. 

While no final decision has been made, BMO analysts noted that “PrEP has been a key area of focus for investors in recent months with the potential launch of Gilead (NASDAQ:GILD)’s new long-acting PrEP medication lenacapavir slated for summer 2025.”

Oppenheimer analysts also downplayed the risk, stating that while federal prevention funding is in question, it would not affect reimbursement for preventative treatments like lenacapavir. 

“Right now, PrEP revenues account for roughly 8% of Gilead’s total revenues, and a smaller portion of that is Medicaid patients, the primary beneficiaries of federal aid,” they wrote. Oppenheimer maintains an Outperform rating with a $132 price target, expecting most initial uptake of lenacapavir to be covered by private insurance.

Truist analysts dismissed the potential funding cut as “a nothingburger,” arguing that the CDC’s budget also covers other infectious diseases, not just HIV, and that HIV drug reimbursement and national coverage would remain intact.

Despite the market reaction, analysts appear largely unconcerned about the long-term impact on Gilead’s business.

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.